{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T23:30:57Z","timestamp":1794526257202,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019084","name":"Kobe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019084","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Fabry disease is an X-linked lysosomal storage disorder caused by insufficient \u03b1-galactosidase A (GLA) activity resulting from variants in the<jats:italic>GLA<\/jats:italic>gene, which leads to glycosphingolipid accumulation and life-threatening, multi-organ complications. Approximately 50 variants have been reported that cause splicing abnormalities in<jats:italic>GLA<\/jats:italic>. Most were found within canonical splice sites, which are highly conserved GT and AG splice acceptor and donor dinucleotides, whereas one-third were located outside canonical splice sites, making it difficult to interpret their pathogenicity. In this study, we aimed to investigate the genetic pathogenicity of variants located in non-canonical splice sites within the<jats:italic>GLA<\/jats:italic>gene.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>13 variants, including four deep intronic variants, were selected from the Human Gene Variant Database Professional. We performed an<jats:italic>in vitro<\/jats:italic>splicing assay to identify splicing abnormalities in the variants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All candidate non-canonical splice site variants in<jats:italic>GLA<\/jats:italic>caused aberrant splicing. Additionally, all but one variant was protein-truncating. The four deep intronic variants generated abnormal transcripts, including a cryptic exon, as well as normal transcripts, with the proportion of each differing in a cell-specific manner.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Validation of splicing effects using an<jats:italic>in vitro<\/jats:italic>splicing assay is useful for confirming pathogenicity and determining associations with clinical phenotypes.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s10157-023-02361-x","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T04:20:07Z","timestamp":1685506807000},"page":"737-746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["All reported non-canonical splice site variants in GLA cause aberrant splicing"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5097-2076","authenticated-orcid":false,"given":"Eri","family":"Okada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Horinouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Aoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kitakado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Ishiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"China","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Ishimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joichi","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandai","family":"Nozu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"2361_CR1","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry\u2019s disease: ceramidetrihexosidase deficiency. N Engl J Med. 1967;276:1163\u20137.","journal-title":"N Engl J Med"},{"key":"2361_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"key":"2361_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1056\/NEJM199508033330504","volume":"333","author":"S Nakao","year":"1995","unstructured":"Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, et al. An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288\u201393.","journal-title":"N Engl J Med"},{"key":"2361_CR4","doi-asserted-by":"crossref","unstructured":"Elleder M, Bradov\u00e1 V, Sm\u00edd F, Bud\u0115s\u00ednsk\u00fd M, Harzer K, Kustermann-Kuhn B, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry\u2019s disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol. 1990;417:449\u201355.","DOI":"10.1007\/BF01606034"},{"key":"2361_CR5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","volume":"64","author":"S Nakao","year":"2003","unstructured":"Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype. Kidney Int. 2003;64:801\u20137.","journal-title":"Kidney Int"},{"key":"2361_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s13353-018-0444-7","volume":"59","author":"A Anna","year":"2018","unstructured":"Anna A, Monika G. Splicing mutations in human genetic disorders: examples, detection, and confirmation. J Appl Genet. 2018;59:253\u201368.","journal-title":"J Appl Genet"},{"key":"2361_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/humu.21445","volume":"32","author":"J Thusberg","year":"2011","unstructured":"Thusberg J, Olatubosun A, Vihinen M. Performance of mutation pathogenicity prediction methods on missense variants. Hum Mutat. 2011;32:358\u201368.","journal-title":"Hum Mutat"},{"key":"2361_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/gim.2013.176","volume":"16","author":"X Jian","year":"2014","unstructured":"Jian X, Boerwinkle E, Liu X. In silico tools for splicing defect prediction: a survey from the viewpoint of end users. Genet Med. 2014;16:497\u2013503.","journal-title":"Genet Med"},{"key":"2361_CR9","doi-asserted-by":"publisher","first-page":"841391","DOI":"10.3389\/fmed.2022.841391","volume":"9","author":"T Yamamura","year":"2022","unstructured":"Yamamura T, Horinouchi T, Aoto Y, Lennon R, Nozu K. The contribution of COL4A5 splicing variants to the pathogenesis of X-linked Alport syndrome. Front Med (Lausanne). 2022;9:841391.","journal-title":"Front Med (Lausanne)"},{"key":"2361_CR10","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1681\/ASN.2018030228","volume":"29","author":"T Horinouchi","year":"2018","unstructured":"Horinouchi T, Nozu K, Yamamura T, Minamikawa S, Omori T, Nakanishi K, et al. Detection of splicing abnormalities and genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol. 2018;29:2244\u201354.","journal-title":"J Am Soc Nephrol"},{"key":"2361_CR11","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1016\/j.ekir.2021.07.010","volume":"6","author":"Y Tsuji","year":"2021","unstructured":"Tsuji Y, Yamamura T, Nagano C, Horinouchi T, Sakakibara N, Ishiko S, et al. Systematic review of genotype-phenotype correlations in Frasier syndrome. Kidney Int Rep. 2021;6:2585\u201393.","journal-title":"Kidney Int Rep"},{"key":"2361_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ekir.2021.10.012","volume":"7","author":"Y Aoto","year":"2022","unstructured":"Aoto Y, Horinouchi T, Yamamura T, Kondo A, Nagai S, Ishiko S, et al. Last nucleotide substitutions of COL4A5 exons cause aberrant splicing. Kidney Int Rep. 2022;7:108\u201316.","journal-title":"Kidney Int Rep"},{"key":"2361_CR13","doi-asserted-by":"crossref","unstructured":"Rossanti R, Horinouchi T, Yamamura T, Nagano C, Sakakibara N, Ishiko S, et al. Evaluation of suspected autosomal Alport syndrome synonymous variants. Kidney360. 2022;3:497\u2013505.","DOI":"10.34067\/KID.0005252021"},{"key":"2361_CR14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s10157-020-01876-x","volume":"24","author":"T Inoue","year":"2020","unstructured":"Inoue T, Nagano C, Matsuo M, Yamamura T, Sakakibara N, Horinouchi T, et al. Functional analysis of suspected splicing variants in CLCN5 gene in Dent disease 1. Clin Exp Nephrol. 2020;24:606\u201312.","journal-title":"Clin Exp Nephrol"},{"key":"2361_CR15","doi-asserted-by":"crossref","first-page":"5614058","DOI":"10.1155\/2016\/5614058","volume":"2016","author":"R Tang","year":"2016","unstructured":"Tang R, Prosser DO, Love DR. Evaluation of bioinformatic programmes for the analysis of variants within splice site consensus regions. Adv Bioinform. 2016;2016:5614058.","journal-title":"Adv Bioinform"},{"key":"2361_CR16","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41436-020-0766-9","volume":"22","author":"HA Wai","year":"2020","unstructured":"Wai HA, Lord J, Lyon M, Gunning A, Kelly H, Cibin P, et al. Blood RNA analysis can increase clinical diagnostic rate and resolve variants of uncertain significance. Genet Med. 2020;22:1005\u201314.","journal-title":"Genet Med"},{"key":"2361_CR17","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1261\/rna.876308","volume":"14","author":"Z Wang","year":"2008","unstructured":"Wang Z, Burge CB. Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. RNA. 2008;14:802\u201313.","journal-title":"RNA"},{"key":"2361_CR18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrg2164","volume":"8","author":"GS Wang","year":"2007","unstructured":"Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet. 2007;8:749\u201361.","journal-title":"Nat Rev Genet"},{"key":"2361_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson JT, Thorvaldsd\u00f3ttir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011;29:24\u20136.","journal-title":"Nat Biotechnol"},{"key":"2361_CR20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/15476286.2020.1809195","volume":"18","author":"N Sakaguchi","year":"2021","unstructured":"Sakaguchi N, Suyama M. In silico identification of pseudo-exon activation events in personal genome and transcriptome data. RNA Biol. 2021;18:382\u201390.","journal-title":"RNA Biol"},{"key":"2361_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"2361_CR22","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123:416\u201327.","journal-title":"Mol Genet Metab"},{"key":"2361_CR23","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/jhg.2016.52","volume":"61","author":"J Seo","year":"2016","unstructured":"Seo J, Kim M, Hong GR, Kim DS, Son JW, Cho IJ, et al. Fabry disease in patients with hypertrophic cardiomyopathy: a practical approach to diagnosis. J Hum Genet. 2016;61:775\u201380.","journal-title":"J Hum Genet"},{"key":"2361_CR24","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/BF03401993","volume":"5","author":"AK Topaloglu","year":"1999","unstructured":"Topaloglu AK, Ashley GA, Tong B, Shabbeer J, Astrin KH, Eng CM, et al. Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease. Mol Med. 1999;5:806\u201311.","journal-title":"Mol Med"},{"key":"2361_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.gene.2015.12.024","volume":"578","author":"C Zizzo","year":"2016","unstructured":"Zizzo C, Monte I, Pisani A, Fatuzzo P, Riccio E, Rodolico MS, et al. Molecular and clinical studies in five index cases with novel mutations in the GLA gene. Gene. 2016;578:100\u20134.","journal-title":"Gene"},{"key":"2361_CR26","doi-asserted-by":"publisher","first-page":"e7387","DOI":"10.1097\/MD.0000000000007387","volume":"96","author":"JH Choi","year":"2017","unstructured":"Choi JH, Lee BH, Heo SH, Kim GH, Kim YM, Kim DS, et al. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: underdiagnosis of late-onset phenotype. Medicine. 2017;96:e7387.","journal-title":"Medicine"},{"key":"2361_CR27","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/jhg.2010.58","volume":"55","author":"BH Lee","year":"2010","unstructured":"Lee BH, Heo SH, Kim GH, Park JY, Kim WS, Kang DH, et al. Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns. J Hum Genet. 2010;55:512\u20137.","journal-title":"J Hum Genet"},{"key":"2361_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/prot.24708","volume":"83","author":"C Riera","year":"2015","unstructured":"Riera C, Lois S, Dom\u00ednguez C, Fernandez-Cadenas I, Montaner J, Rodr\u00edguez-Sureda V, de la Cruz X. Molecular damage in Fabry disease: characterization and prediction of alpha-galactosidase A pathological mutations. Proteins. 2015;83:91\u2013104.","journal-title":"Proteins"},{"key":"2361_CR29","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","volume":"123","author":"A Nowak","year":"2018","unstructured":"Nowak A, Mechtler TP, Hornemann T, Gawinecka J, Theswet E, Hilz MJ, Kasper DC. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease. Mol Genet Metab. 2018;123:148\u201353.","journal-title":"Mol Genet Metab"},{"key":"2361_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/1479-7364-2-5-297","volume":"2","author":"J Shabbeer","year":"2006","unstructured":"Shabbeer J, Yasuda M, Benson SD, Desnick RJ. Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations. Hum Genom. 2006;2:297\u2013309.","journal-title":"Hum Genom"},{"key":"2361_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ymeth.2005.07.015","volume":"37","author":"TA Cooper","year":"2005","unstructured":"Cooper TA. Use of minigene systems to dissect alternative splicing elements. Methods. 2005;37:331\u201340.","journal-title":"Methods"},{"key":"2361_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/8904_2015_475","volume":"30","author":"T Higuchi","year":"2016","unstructured":"Higuchi T, Kobayashi M, Ogata J, Kaneshiro E, Shimada Y, Kobayashi H, et al. Identification of cryptic novel \u03b1-galactosidase A gene mutations: abnormal mRNA splicing and large deletions. JIMD Rep. 2016;30:63\u201372.","journal-title":"JIMD Rep"},{"key":"2361_CR33","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/ejhg.2008.109","volume":"16","author":"C Filoni","year":"2008","unstructured":"Filoni C, Caciotti A, Carraresi L, Donati MA, Mignani R, Parini R, et al. Unbalanced GLA mRNAs ratio quantified by real-time PCR in Fabry patients\u2019 fibroblasts results in Fabry disease. Eur J Hum Genet. 2008;16:1311\u20137.","journal-title":"Eur J Hum Genet"},{"key":"2361_CR34","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1086\/339431","volume":"70","author":"S Ishii","year":"2002","unstructured":"Ishii S, Nakao S, Minamikawa-Tachino R, Desnick RJ, Fan JQ. Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am J Hum Genet. 2002;70:994\u20131002.","journal-title":"Am J Hum Genet"},{"key":"2361_CR35","doi-asserted-by":"crossref","first-page":"e1342","DOI":"10.1002\/mgg3.1342","volume":"8","author":"T Horinouchi","year":"2020","unstructured":"Horinouchi T, Yamamura T, Minamikawa S, Nagano C, Sakakibara N, Nakanishi K, et al. Pathogenic evaluation of synonymous COL4A5 variants in X-linked Alport syndrome using a minigene assay. Mol Genet Genom Med. 2020;8:e1342.","journal-title":"Mol Genet Genom Med"},{"key":"2361_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/TACG.S146022","volume":"12","author":"JP Oliveira","year":"2019","unstructured":"Oliveira JP, Ferreira S. Multiple phenotypic domains of Fabry disease and their relevance for establishing genotype- phenotype correlations. Appl Clin Genet. 2019;12:35\u201350.","journal-title":"Appl Clin Genet"},{"key":"2361_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13023-022-02377-8","volume":"17","author":"X Dai","year":"2022","unstructured":"Dai X, Zong X, Pan X, Lu W, Jiang GR, Lin F. Identification and functional characterization of the first deep intronic GLA mutation (IVS4+1326C>T) causing renal variant of Fabry disease. Orphanet J Rare Dis. 2022;17:237.","journal-title":"Orphanet J Rare Dis"},{"key":"2361_CR38","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ymgme.2017.06.002","volume":"123","author":"HC Liao","year":"2018","unstructured":"Liao HC, Hsu TR, Young L, Chiang CC, Huang CK, Liu HC, et al. Functional and biological studies of \u03b1-galactosidase A variants with uncertain significance from newborn screening in Taiwan. Mol Genet Metab. 2018;123:140\u20137.","journal-title":"Mol Genet Metab"},{"key":"2361_CR39","doi-asserted-by":"crossref","unstructured":"Chiang HL, Wang NH-H, Song IW, Chang CP, Wen MS, Chien YH, et al. Genetic epidemiological study doesn\u2019t support GLA IVS4+919G>A variant is a significant mutation in Fabry disease. Mol Genet Metab. 2017;121:22\u20137.","DOI":"10.1016\/j.ymgme.2017.03.005"},{"key":"2361_CR40","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.1038\/mtna.2016.88","volume":"5","author":"L Ferri","year":"2016","unstructured":"Ferri L, Covello G, Caciotti A, Guerrini R, Denti MA, Morrone A. Double-target antisense U1snRNAs correct mis-splicing due to c.639+861C>T and c.639+919G>A GLA deep intronic mutations. Mol Ther Nucleic Acids. 2016;5:e380.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2361_CR41","doi-asserted-by":"publisher","first-page":"e0175929","DOI":"10.1371\/journal.pone.0175929","volume":"12","author":"WH Chang","year":"2017","unstructured":"Chang WH, Niu DM, Lu CY, Lin SY, Liu TC, Chang JG. Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry disease. PLoS ONE. 2017;12:e0175929.","journal-title":"PLoS ONE"},{"key":"2361_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","volume":"65","author":"C Whybra","year":"2004","unstructured":"Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson\u2013Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet. 2004;65:299\u2013307.","journal-title":"Clin Genet"},{"key":"2361_CR43","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cca.2014.08.002","volume":"438","author":"C Auray-Blais","year":"2015","unstructured":"Auray-Blais C, Blais CM, Ramaswami U, Boutin M, Germain DP, Dyack S, et al. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. Clin Chim Acta. 2015;438:195\u2013204.","journal-title":"Clin Chim Acta"},{"key":"2361_CR44","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ymgme.2014.02.004","volume":"111","author":"SH Lee","year":"2014","unstructured":"Lee SH, Li CF, Lin HY, Lin CH, Liu HC, Tsai SF, Niu DM. High-throughput detection of common sequence variations of Fabry disease in Taiwan using DNA mass spectrometry. Mol Genet Metab. 2014;111:507\u201312.","journal-title":"Mol Genet Metab"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02361-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-023-02361-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02361-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T12:42:48Z","timestamp":1702557768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-023-02361-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2361"],"URL":"https:\/\/doi.org\/10.1007\/s10157-023-02361-x","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"assertion":[{"value":"26 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study were carried out according to the ethical standards of the Institutional Review Board of Kobe University Graduate School of Medicine (IRB approval nos. 65 and 301) and with the 1964 Helsinki Declaration and its later amendments on comparable ethical standards. Comprehensive informed consent was obtained from all participants in the study and\/or their guardians regarding the use of the patients\u2019 clinical data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}